Diamonds and Dogs

9/14/15

The markets are taking a bite out of Raptor Pharmaceuticals (RPTP) today. Raptor is down 37% after the announcement that their experimental drug for nonalcoholic steatohepatitis (NASH) in children, RP103, failed to meet its primary endpoint in a second mid-stage trial. Because RP103 reportedly failed to make any meaningful impact on liver fibrosis, Raptor expects to discontinue the drug's clinical program for NASH following these disappointing results. Let's hope the company finds success with their other drugs.

GoPro is bouncing back today. GoPro (GPRO) has had a tough month and a half. At the start of August everyone loved the stock above $60, but now with the stock nearly cut in half, the analyst community has been quiet until today. An analyst at Northland Securities made comments today saying the sell-off in GoPro has provided a compelling entry point. The analyst believes the caution about slowing sales for the GoPro cameras has been priced in and the growing sports content and video ecosystem make it a compelling acquisition target for Apple or another company down the road.

Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.